William Kevin Kelly

Fasting-Based Dietary Interventions in Cancer Patients and Survivors: A Scoping Review

Kuang‐Yi Wen, Julianne Freedman, Abenezer Melaku Tafese, William Kevin Kelly et autres

Background: Fasting-based interventions are increasingly investigated as adjuncts to cancer treatment for the potential to reduce therapy-related toxicities, improve metabolic health, and enhance quality of life. However, clinical evidence regarding their efficacy, tolerability, and acceptability remains limited and fragmented. This scoping review …

us (code pays fourni par la source)

Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer

Susan Halabi, Siyuan Guo, Bin Luo, Chenxi Yu et autres

BACKGROUND AND OBJECTIVE: Although validated prognostic models exist for men with metastatic castration-resistant prostate cancer (mCRPC), current tools do not incorporate genomic biomarkers such as circulating tumor DNA (ctDNA) aneuploidy or pathogenic genetic alterations (PGAs). This study aimed to estimate the prevalence …

us (code pays fourni par la source)

Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy

Marianela Schiava, Yolande Parkhurst, Matthew Henderson, Tuomo M. Polvikoski et autres

Background and Objectives: Valosin Containing Protein-associated multisystem proteinopathy (VCP-MSP) is a progressive, autosomal dominant disorder caused by pathogenic variants in the VCP gene, resulting in a heterogeneous clinical presentation. Muscle biopsy findings are characteristic but not pathognomonic. This study aimed to comprehensively …

gb, us, jp, fr, it, at, be, cl, cn, gr, hu, pl, nl, es, se, de (code pays fourni par la source)

Irradiation of prostate cancer alters circulating small extracellular vesicle functions

Aejaz Sayeed, Vaughn Garcia, Cecilia E. Verrillo, Rachel M. DeRita et autres

It is known that β1 integrins and a downstream signaling molecule c-Src are upregulated in prostate cancer (PrCa) tissues, are co-expressed in circulating small extracellular vesicles (sEVs) and contribute to cancer progression. Here, we demonstrate that sEVs from PrCa patients show robust …

us (code pays fourni par la source)

Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).

William Kevin Kelly, Michael J. Morris, Lisa Kristina Horvath, Viktor Grünwald et autres

TPS5118 Background: The median overall survival of patients with mCRPC remains under 2 years even with newer therapies. Xaluritamig, an XmAb 2+1 T-cell engager that targets the six-transmembrane epithelial antigen of prostate 1 (STEAP1), facilitates lysis of STEAP1-expressing cancer cells, such as …

us, au, de, gb, fr, ca, es, ch, jp (code pays fourni par la source)

Molecular characterization of STEAP1 and -2 in advanced prostate cancer.

Kevin Kayvan Zarrabi, Tolulope Tosin Adeyelu, Andrew Elliott, Daniel M. Geynisman et autres

5072 Background: STEAP 1 and 2 (six-transmembrane epithelial antigen of prostate) are metalloreductase proteins involved in a variety of biologic processes. STEAP1/2 are tumor-associated cell surface antigens highly expressed in prostate cancer (PC), although their role in cancer is poorly understood. STEAP1/2 …

us (code pays fourni par la source)

Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Guanglong Jiang, Jai Narendra Patel, Mark J. Ratain, Jin Wang et autres

us (code pays fourni par la source)

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Bryan Paul Schneider, Mark J. Ratain, Jin Wang, Flora A. Mulkey et autres

us (code pays fourni par la source)

Abstract 502: Exploring STEAP1 expression in prostate cancer cells in response to androgen deprivation and in small extracellular vesicles

Candice L. Bizzaro, Rayane Dantas Dos Santos, Cecilia E. Verrillo, Nicole M. Naranjo et autres

Abstract The Six Transmembrane Epithelial Antigen of the Prostate (STEAP1 and 2) metalloreductases are therapeutic targets for advanced PCa, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and function of STEAP in PCa progression remains …

us, ar (code pays fourni par la source)

Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.

Nicholas A. Zorko, Vivek K. Narayan, Biren Saraiya, William J. Tester et autres

128 Background: T-cell engaging bsAbs and CAR T-cell therapy have shown exceptional success in treating multiple hematologic malignancies. More recently, bsAbs have been FDA-approved to treat uveal melanoma and small cell lung cancer, demonstrating proof-of-concept for immune therapies beyond checkpoint inhibition to …

us (code pays fourni par la source)

A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).

Bilal Ahmed Siddiqui, Benedito A. Carneiro, Mark N. Stein, Jingsong Zhang et autres

TPS293 Background: Advanced mCRPC and metastatic ccRCC are urologic malignancies with poor prognoses, and novel therapies that can improve long-term outcomes remain an unmet medical need. Prostate-specific membrane antigen (PSMA) is a validated therapeutic target for prostate cancer. It is a transmembrane …

us (code pays fourni par la source)

Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

William Kevin Kelly, Sandy Srinivas, Joseph J. Maly, Deepak Kilari et autres

TPS295 Background: mCRPC is characterized by an immunosuppressive tumor microenvironment with few intratumoral effector T cells, leading to low response rates to immune checkpoint inhibitors; therefore, novel immunotherapy approaches are needed. Prostate-specific membrane antigen (PSMA) is highly expressed in malignant prostate cancer …

us (code pays fourni par la source)